Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals plc is soliciting proxies for its 2026 Annual General Meeting to be held on July 23, 2026 at its Dublin headquarters. Shareholders of record as of May 28, 2026 may vote on election of three Class III director nominees for three‑year terms, ratification of KPMG as auditor, a non‑binding say‑on‑pay, and two resolutions renewing board authority to allot and issue ordinary shares (including a special resolution to opt out of pre‑emption rights for issuances for cash up to 20% of issued ordinary share capital). Proxy voting deadlines and methods are described, and management will present Irish statutory financial statements for the year ended December 31, 2025.
Jazz Pharmaceuticals plc reported that director Anne O’Riordan, a Class III director whose term expires at the Company’s 2026 annual meeting of shareholders, has informed the board that she will not stand for re-election. The company notes this decision is not due to any dispute or disagreement with the company or its board on operations, policies, or practices. The board emphasized its commitment to ongoing board refreshment, board effectiveness, and orderly succession processes.
Jazz Pharmaceuticals director Rick E. Winningham exercised stock options and sold shares in the company. On May 22, 2026, he sold 2,741 Ordinary Shares in an open-market transaction at $241.57 per share, and exercised 3,415 Non-Qualified Stock Options at a $138.08 exercise price.
The options were originally granted in August 2016 and had fully vested by August 1, 2017. Following these transactions, Winningham directly holds 9,567 Ordinary Shares of Jazz Pharmaceuticals, indicating he retained a meaningful equity stake after the exercise-and-sale activity.
Jazz Pharmaceuticals plc director Heather Ann McSharry reported an open-market sale of 2,000 Ordinary Shares of the company on May 22, 2026 at a price of $241.00 per share. After this transaction, she directly holds 18,449 Ordinary Shares of Jazz Pharmaceuticals.
Filer submitted a Form 144 to propose the sale of 2,000 shares of Common Stock. The filing lists a cash amount of $482,000.00 and an identifier 62742820 with an execution date of 05/22/2026.
The excerpt shows two tranches of restricted stock with grant dates and quantities: 667 shares dated 08/07/2015 and 1,333 shares dated 05/11/2015. The filing notes these securities are to be sold and records no reported sales in the past three months in the provided excerpt.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of Jazz Pharmaceuticals on May 1, 2026, at $203.33 per share. After this transaction, he directly holds 378,682 Ordinary Shares.
According to the filing, this sale was executed automatically under a pre-arranged trading plan adopted on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, meaning the timing did not involve a discretionary decision by Cozadd.
Jazz Pharmaceuticals reported sharply improved results for the quarter ended March 31, 2026. Total revenues rose to $1,068.9 million from $897.8 million, driven by higher product sales across sleep, epilepsy and oncology franchises.
Net income reached $293.1 million, compared with a net loss of $92.5 million a year earlier, helped by a $122.8 million gain on the sale of a rare pediatric disease priority review voucher and lower selling, general and administrative expenses. Cash and cash equivalents increased to $1,844.3 million, while total debt remained around $5.35 billion, leaving the company with significant liquidity to support its rare disease portfolio and R&D pipeline.